Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 30, 2008 Brian Orelli	Johnson & Johnson Grows Up a Little Its Concerta for attention-deficit disorder is approved for use in adults.
American Family Physician November 1, 2000	When Adults Have ADHD Attention-deficit/hyperactivity disorder is also called ADHD. People with ADHD are hyperactive or distracted most of the time. Even when they try to concentrate, they find it hard to pay attention...
American Family Physician November 1, 2000 Searight, Burke & Rottnek	Adult ADHD: Evaluation and Treatment in Family Medicine Attention-deficit/hyperactivity disorder (ADHD) affects 30 to 50 percent of adults who had ADHD in childhood. Accurate diagnosis of ADHD in adults is challenging and requires attention to early development and symptoms of inattention, distractibility, impulsivity and emotional lability...
ifeminists May 24, 2006 Gerald K. McOscar	ADHD Is it child abuse per se for parents to allow doctors to prescribe mind altering drugs with potentially serious or fatal psychiatric side effects to their children, no matter how challenged...or challenging?
Managed Care June 2006	More Young Adults Prescribed ADHD Drugs The number of adults ages 20 to 44 prescribed attention deficit hyperactivity disorder medications increased about 140% from 2000 to 2005. This was even faster growth than the 82% reported for children.
Salon.com October 18, 2001 Lawrence H. Diller	An end run to marketing victory Drug makers find ways to circumvent an advertising ban and promote psychiatric drugs for children...
BusinessWeek March 27, 2006 Gene G. Marcial	Cortex Draws A Bead On Hyperactivity When Cortex Pharmaceuticals disclosed on Mar. 8 that its lead drug, CX717, showed favorable results in Phase 2 trials for the treatment of adult ADHD, the stock jumped.
American Family Physician May 1, 2001	Learning About ADHD in Children ADHD, or attention-deficit/hyperactivity disorder, is a common health problem in children. Children with ADHD are hyperactive--they can't sit still. They are also impulsive and easily distracted. They have trouble coping at school and at home...
ifeminists February 25, 2007 Tony Zizza	ADHD and Coca-Cola Come Up Flat The selling and marketing of alleged mental disorders remains a part of our popular culture. Ever since the FDA finally put black box warnings on ADHD drugs for children, drug companies and the mainstream media have been trying to convince adults that they also suffer from ADHD.
The Motley Fool May 2, 2007 Mike Havrilla	Consider Cortex New findings may give Cortex's ADHD drug the lift it needs. The news represents an excellent opportunity for speculative biotech investors
Salon.com March 9, 2000 Lawrence H. Diller, M.D.	Kids on drugs A behavioral pediatrician questions the wisdom of medicating our children.
The Motley Fool October 30, 2006 Brian Lawler	Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note.
American Family Physician October 15, 2001 Michael L. Szymanski	Attention-Deficit/Hyperactivity Disorder: Management Attention-deficit/hyperactivity disorder (ADHD) is the most common psychiatric disorder of childhood and often persists into adulthood. With time and interest, the family physician can develop the skills needed to treat this disorder...
American Family Physician September 1, 2001 William D. Smucker & Marjaneh Hedayat	Evaluation and Treatment of ADHD Symptoms of attention-deficit/hyperactivity disorder (ADHD) are present in as many as 9 percent of school-age children. ADHD-specific questionnaires can help determine whether children meet diagnostic criteria for the disorder...
Salon.com May 23, 2002 Lawrence H. Diller	A prescription for disaster The failure to test the effects in children of routinely prescribed drugs has resulted in at least one death. How many kids will die before drug companies take steps to ensure their safety?
The Motley Fool August 19, 2004 Charly Travers	1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL.
The Motley Fool February 26, 2007 Brian Lawler	Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition.
Salon.com October 25, 2000 Cynthia Kuhn & Wilkie Wilson	Cured but worried I've been taking medication for my attention-deficit disorder. The drug really helps, but I'm afraid of its long-term effects...
BusinessWeek November 1, 2004 Amy Barrett	This Pep Pill is Pushing Its Luck Half of Provigil prescriptions may be for "off-label" uses. Did its maker cross the line? But Cephalon is hardly the only drugmaker in the spotlight.
The Motley Fool October 9, 2006 Brian Lawler	New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up.
The Motley Fool September 5, 2007 Brian Lawler	Not Your Typical Product Recall Shire and Noven will fix an annoying foible of their ADHD patch, Daytrana, making the back adhesive easier to unpeel.
Wired September 25, 2007 Patrick Di Justo	From Benzedrine to Abilify, Chronicling America's Love of Psychiatric Drugs A history of what Americans have used to battle depression.
The Motley Fool October 9, 2007 Brian Lawler	Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises.
The Motley Fool July 27, 2007	Shire's Got Focus: Fool by Numbers Revenue and guidance are up at Shire, led by improved sales of their ADHD drugs.
The Motley Fool March 24, 2006 Brian Gorman	Cephalon Takes a Hit The FDA rules against its ADHD drug, but Cephalon's current lineup still holds promise. Investors may want to look at the current sell-off as a potential buying opportunity.
BusinessWeek October 24, 2005 Gene G. Marcial	Undivided Attention For An ADHD Battle Sales of Shire Pharmaceuticals' Adderall XR, the leading ADHD drug, are up.
Scientific American July 2005 Gunjan Sinha	Training the Brain Cognitive therapy as an alternative to ADHD drugs.
American Family Physician May 1, 2001 Carla T. Herrerias	The Child with ADHD: Using the AAP Clinical Practice Guideline The American Academy of Pediatrics developed an evidence-based clinical practice guideline that provides recommendations for the assessment and diagnosis of school-aged children with attention-deficit/hyperactivity disorder...
Pharmaceutical Executive June 1, 2012	Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
Nursing April 2008 Kathryn Murphy	Shedding the burden of depression & anxiety Learn about types of depression and available treatments.
Salon.com September 25, 2000 Lawrence H. Diller, M.D.	Just say yes to Ritalin! Parents are being pressured by schools to medicate their kids -- or else.
American Family Physician January 1, 2007 Shashi & Subhash Bhatia	Childhood and Adolescent Depression Safe and effective treatment of major depression in this age group requires accurate diagnosis, suicide risk assessment, and use of evidence-based therapies.
BusinessWeek August 22, 2005 Gene G. Marcial	New River May Have A "Blockbuster" For ADHD New River Pharmaceuticals has yet to make a dime - but investors love it.
ifeminists June 21, 2006 Tony Zizza	Tom Cruise Was - Right! In American, when even choosing to be a jerk in your automobile is now viewed as suffering from a mental disorder that requires therapy and drugs, psychiatry is 100% -- pseudoscience.
American Family Physician April 15, 2001 H. Russell Searight	Conduct Disorder: Diagnosis and Treatment in Primary Care Conduct disorder is a common childhood psychiatric problem that has an increased incidence in adolescence. The primary diagnostic features of conduct disorder include aggression, theft, vandalism, violations of rules and/or lying...
ifeminists May 10, 2006 Tony Zizza	Is It Time To Boycott Parade Magazine? Once again Parade magazine is helping pharmaceutical companies sell depression and its drugs. If we are to take AstraZeneca seriously, and bipolar disorder seriously, then we must completely reject the idea of free will, personal responsibility, and good/bad consequences.
The Motley Fool December 5, 2005 W.D. Crotty	Cashing In on Noven's Drug Patch An FDA advisory panel recommends approval of Noven's patch for attention deficit hyperactivity. For now, investors might be put off by the company's lofty valuation of 55 times trailing earnings.
The Motley Fool August 28, 2008 Brian Orelli	Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them.
Inc. February 2005 David Dent	The ADD Dilemma Some eight million Americans have attention deficit disorder. One of them may work for you. Or be you. Why are people with ADD disproportionately drawn to owning their own business?
ifeminists July 26, 2006 Tony Zizza	Are Affluent Teens The Latest Victims Of Mental Illness? Everything in America is viewed through the prism of alleged mental illness. Affluent teenagers are just today's advertising copy for the next psych drug and insurance billing code.
The Motley Fool November 9, 2006 Brian Lawler	Noven Might Be in a Purple Patch Investors in Noven shares might as well pay most of their attention to Shire, because as long as Daytrana does well, so too will Noven.
ifeminists December 28, 2005 Tony Zizza	If Depression Hurts, Eli Lilly Is Killing Us Eli Lilly's latest marketing campaign is a form of propaganda that speaks to how low Big Pharma will go to keep Americans in chemical handcuffs.
American Family Physician November 15, 2000 Son & Kirchner	Depression in Children and Adolescents Depression among children and adolescents is common but frequently unrecognized. It affects 2 percent of prepubertal children and 5 to 8 percent of adolescents...
The Motley Fool December 26, 2006 Brian Lawler	Barely a Ripple for New River With New River's $2 billion market cap, no recurring revenues to speak of, and the terms of its partnership with Shire still uncertain, these shares are more than a tad too rich.
The Motley Fool June 18, 2009 Brian Orelli	Your Stocks Just Got Riskier It's been a busy week for the Food and Drug Administration, and not in the bust-out-the-champagne-we-got-an-approval way. Is the FDA cracking down on pharmaceutical companies?
ifeminists March 17, 2004 Tony Zizza	"What Do You Want To Do?" Surely, we will all yell (bravo!) when mental health professionals who have prescription pads burning in their pockets, and pharmaceutical executives come to understand, we need more compassionate psychologists in this country and fewer prescriptions.
Nutrition Action Healthletter March 2000	Diet & Behavior in Children While stimulant drugs can help keep a child's hyperactivity under control, they can also have side effects like reduced appetite, weight loss, stomachaches, insomnia...or worse.
The Motley Fool August 7, 2008 Brian Orelli	The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates.
Entrepreneur September 2005 Mark Henricks	Disorderly Conduct Some entrepreneurs -- including some very famous ones -- have made their quirks work for them.
Managed Care June 2004	Use of Attention-Deficit Medications Surges 369 Percent in Children Under 5 ADHD medication spending for pediatric patients outpaces antibiotics, allergy, and asthma treatments.